Table 1.

Clinical characteristics of 40 patients with plaque stage folliculotropic mycosis fungoides

	Total group (n = 40)	NP‐FMF (n = 20)	P‐FMF (n = 20)	P‐value
Median age at diagnosis (range; months)	56 (19‐82)	51 (19‐68)	62 (29‐82)	<0.01
Male‐female (ratio)	29‐11 (2.6)	15‐5 (3.0)	14‐6 (2.3)	0.72
Median time from first skin lesion to diagnosis (months)	24 (3‐300)	10 (2‐360)	36 (3‐300)	0.19
Extent of skin lesions				0.11
Solitary	2 (5%)	2 (10%)	0
Localized	2 (5%)	2 (10%)	0
Generalized	36 (90%)	16 (80%)	20 (100%)
Predominant head/neck involvement	32 (80%)	16 (80%)	16 (80%)	1.0
Pruritus				0.34
Yes	30 (75%)	13 (65%)	17 (85%)
No	8 (20%)	5 (25%)	3 (15%)
Unknown	2 (5%)	2 (10%)	—
Type of initial treatment				0.61
Topical steroids	4 (10%)	3 (15%)	1 (5%)
Narrow‐band UVB	2 (5%)	0 (0%)	2 (10%)
PUVA	16 (40%)	9 (45%)	7 (35%)
PUVA + local radiotherapy	6 (15%)	2 (10%)	4 (20%)
Local radiotherapy	6 (15%)	3 (15%)	3 (15%)
Total skin radiotherapy	6 (15%)	3 (15%)	3(15%)
Result initial treatment				0.03
Complete remission	15 (37%)	12 (60%)	3 (15%)
Partial remission	13 (32%)	3 (15%)	10 (50%)
Stable disease	10 (25%)	4 (20%)	6 (30%)
Progressive disease	2 (5%)	1 (5%)	1 (5%)
Median duration follow‐up (range) (months)	80 (6‐320)	104 (38‐320)	59 (6‐241)	0.05
Status at last follow‐up				<0.01
Alive without disease	7 (17%)	7 (35%)	0 (0%)
Alive with ongoing disease	14 (35%)	10 (50%)	4 (20%)
Died of lymphoma	15 (37%)	0 (0%)	15 (75%)
Died of unrelated disease	4 (10%)	3 (15%)	1 (5%)
Disease‐specific survival at 5/10 years	72%/57%	100%/100%	45%/24%	<0.01
Overall survival at 5/10 years	68%/54%	90%/90%	45%/24%	<0.01

Abbreviations: NP‐FMF: non‐progressive folliculotropic mycosis fungoides; P‐FMF, progressive folliculotropic mycosis fungoides; PUVA: psoralen plus ultraviolet A therapy; UVB: ultraviolet B therapy.